ClinicalTrials.gg
Temporarily not availableNCT06033001Updated Jan 13, 2025

Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

An expanded access record providing [Lu-177]-PNT2002 in Castration-Resistant Prostatic Cancer, sponsored by Lantheus Medical Imaging. Temporarily not available at 7 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-13.

Sponsored by Lantheus Medical Imaging (part of Lantheus Holdings, Inc.) · Expanded access

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Expanded access
Access type
Intermediate-size population
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States — 18 open to participants now, 24 under way, 3 of them phase 3. Prostatic Neoplasms, Castration-Resistant · United States.

Other kind
2 of 51
none open now
Registered
36th of 51
by date

Among the 51 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States, this one is one of 2 of another kind, and was the 36th registered.

Prostatic Neoplasms, Castration-Resistant

86 studies on the registry are indexed under Prostatic Neoplasms, Castration-Resistant; 29 are open to participants now.

Browse Prostatic Neoplasms, Castration-Resistant studies →

Open to participants now

18 of the 51 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 26 Prostatic Neoplasms, Castration-Resistant studies recruiting now, 22 (85%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years and older · male.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States, or all of them as a file.
02

Study summary

The purpose of this program is to provide access to [Lu-177]-PNT2002 to patients who have been diagnosed with prostate-specific membrane antigen (PMSA)-positive castration-resistant prostate cancer (mCRPC). Patients must have received at least 1 prior androgen pathway inhibitor (ARPI) and cannot be treated by currently available drugs or clinical trials.

In this program participants will be administered [Lu-177]-PNT2002 intravenously every 8 weeks (about every 2 months) for 4 cycles, or 8 months of total treatment. During treatment, participants will be monitored with routine laboratory tests such as:

  • Hematology blood tests
  • Clinical Chemistry blood tests
  • Testosterone/Prostate Antigen levels blood test
  • Vital signs
  • Imaging
  • ECG
03

Conditions studied

  • Castration-Resistant Prostatic Cancer

Keywords

  • progressive mCRPC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is male aged 18 years or older;
  2. Histological, pathological, and/or cytological confirmation of adenocarcinoma of the prostate;
  3. Patients must have at least 1 lesion present on CT, MRI, or bone scan imaging;
  4. Patients must have progressive mCRPC based on at least 1 of the following criteria:

    1. Serum/plasma PSA progression defined as increase in PSA greater than 25% and >2 ng/mL above nadir, confirmed by progression at 2 time points at least 3 weeks apart
    2. Soft-tissue progression defined as an increase ≥20% in the sum of the diameters (SOD) (short axis for nodal lesions and long axis for non-nodal lesions) of all target lesions based on the smallest SOD since treatment started or the appearance of one or a new lesion
    3. Progression of bone disease defined as the appearance of 2 or more lesions by bone scan
  5. Progression on prior treatment with ≥1 ARPI (abiraterone, apalutamide, darolutamide, enzalutamide ) in nmCRPC, mHSPC or mCRPC;
  6. PSMA-PET scan ([Ga-68]-PSMA-11 or [F-18]-DCFPyL) positive as determined by local investigator;

    1. At least 1 PSMA-PET positive lesion for prostate cancer
    2. Uptake greater than the liver will be used as the reference for determining PSMA-PET positivity and uptake less than or equal to the liver will be used as the reference for determining PSMA-PET negativity
    3. All lymph nodes that measure ≥25 mm in short axis on anatomic imaging must be PSMA-PET positive
    4. All bone metastases with soft tissue component(s) ≥10 mm in short axis must be PSMA-PET positive (PSMA-negative osseous metastases without a soft tissue component do not exclude patients)
    5. All solid organ metastases (i.e., lung, liver, adrenal glands, etc.) ≥10 mm in short axis must be PSMA-PET positive
  7. Castrate levels of circulating testosterone (\<1.7 nmol/L or \<50 ng/dL);
  8. Patients must have recovered to Grade ≤2 from all toxicities related to; prior therapies (i.e., prior ARPI, chemotherapy, PARPi, radioisotope or immunotherapy, etc.)
  9. Adequate organ function, independent of transfusion;

    a. Bone marrow reserve

    i. White blood cell (WBC) count ≥2.5 x 109/L OR (ANC) ≥1.5 x 109/L ii. ≥100 x 109/L iii. ≥80 g/L or ≥8 g/dL

    b. Liver function

    i. Total ≤1.5 x institutional (ULN). For patients with known Gilbert's syndrome, ≤3.0 x ULN ii. and AST ≤3.0 x ULN

    c. Renal function

    i. ≥50 mL/min based on Cockroft-Gault formula

    d. Albumin ≥30 g/L

  10. -infected patients who are healthy and have a low risk of acquired immunodeficiency syndrome-related outcomes are eligible;
  11. performance status 0 or 1;
  12. For patients who have partners who are pregnant or of : a condom is required along with a highly effective method during the study and for 6 months after last study drug administration. Such methods deemed highly effective include a) combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation, b) progestogen-only hormonal contraception associated with inhibition of ovulation, c) intrauterine device (IUD), d) intrauterine hormone-releasing system (IUS), e) bilateral tubal occlusion, f) vasectomy, g) true sexual abstinence: when this is in line with the preferred and usual lifestyle of the subject [periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of exposure to IMP, and withdrawal are not acceptable methods of abstinence].
  13. Signed Form

Exclusion criteria

Exclusion Criteria:

  1. Prior PSMA-targeted radioligand therapy (i.e., [Lu-177]-PSMA-617);
  2. A superscan defined as a bone scan that demonstrates markedly increased skeletal radioisotope uptake relative to soft tissues in association with absent or faint genitourinary tract activity;
  3. Patients with a history of central nervous system (CNS) must have received therapy (surgery, radiotherapy, gamma knife) and be neurologically stable, asymptomatic, and not receiving for the purposes of maintaining neurologic integrity;
  4. Patients with epidural disease, canal disease and prior cord involvement are eligible if those areas have been treated, are stable, and not neurologically impaired. For patients with parenchymal (or a history or CNS metastasis), baseline and subsequent radiological imaging must include evaluation of the brain (MRI preferred or CT with contrast);
  5. Symptomatic cord compression, or clinical radiologic findings indicative of impending cord compression;
  6. Any pre-existing symptoms, or concurrent severe and/or uncontrolled medical conditions such as ureteral obstruction, which in the opinion of the investigator would compromise safe participation in the [Lu-177]-PNT2002 EAP;
  7. Not able to understand and comply with treatment instructions and requirements;
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Access details

Study type
Expanded access
Access type
Intermediate-size population

Available treatment

  • DrugLutetium Lu 177 Zadavotide GuraxetanStudies of Lutetium Lu 177 Zadavotide GuraxetanLutetium Lu 177 Zadavotide Guraxetan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    \[Lu-177\]-PNT2002, is a radiopharmaceutical investigational drug. \[Lu-177\]-PNT2002 targets a specific protein that is located on the surface of prostate cancer cells called PSMA. \[Lu-177\]-PNT2002 delivers radiation to your cancer by binding to the PSMA which helps destroy the cancer cells. \[Lu-177\]-PNT2002 is administered intravenously every 8 weeks (about every 2 months) for 4 cycles, or 8 months of total treatment.

06

Where to request access

7 sites
  • Hoag Memorial Hospital Presbyterian
    Newport Beach, California 92663, United States
  • Hartford HealthCare Cancer Institute at Hartford Hospital
    Hartford, Connecticut 06106, United States
  • Florida Theranostics Cancer Center
    Jupiter, Florida 33458, United States
  • Biogenix Molecular, LLC
    Miami, Florida 33165, United States
  • Comprehensive Hematology Oncology
    Trinity, Florida 34655, United States
  • BAMF Health, Inc
    Grand Rapids, Michigan 49503, United States
  • John Theurer Cancer Center at Hackensack Meridian University Medical Center
    Hackensack, New Jersey 07601, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT06033001
Responsible party
Sponsor
First posted
Sep 13, 2023
Last update
Jan 13, 2025
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion